Cellulitis is an acute localised skin infection, usually accompanied by symptoms such as fever and rigors, nausea, and vomiting. It most commonly affects the lower limbs, although it can involve any part of the skin. It presents as area of redness and inflammation of the skin, with associated pain and swelling.

[download-attachments container="div" style="list" display_icon="1" display_count="1" display__size="0"]

References

1. Flanagan M. Wound healing and skin integrity: Principles and practice. John Wiley & Sons, Ltd; 2013.
2. Hay RJ, Morris-Jones R. Rook’s Textbook of Dermatology. Vol 3. 9th ed: Wiley; 2016.
3. Health UKDo. Hospital Episode Statistics 2012. http://www.hscic.gov.uk/catalogue/PUB08288/hospepis-stat-admi-primdiag-4cha-11-12-tab.xls. Accessed May, 2015.
4. Eriksson B, Jorup-Ronstrom C, Karkkonen K, Sjoblom AC, Holm SE. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis. 1996;23(5):1091-1098.
5. Morris A. Cellulitis and Erysipelas. In: Board BE, ed. Clinical Evidence. London: BMJ Books; 2001:1146-1149.
6. Cox NH, Colver GB, Paterson WD. Management and morbidity of cellulitis of the leg. J R Soc Med. 1998;91(12):634-637.
7. Jorup-Ronstrom C, Britton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection. 1987;15(2):105-106.
8. Pavlotsky F, Amrani S, Trau H. Recurrent erysipelas: risk factors. J Dtsch Dermatol Ges. 2004;2(2):89-95.
9. Thomas KS, Crook AM, Nunn AJ, et al. Penicillin to prevent recurrent leg cellulitis. N Engl J Med. 2013;368(18):1695-1703.
10. Toleman MS, Vipond IB, Brindle R. Specific PCR, bacterial culture, serology and pharyngeal sampling to enhance the aetiological diagnosis of cellulitis. J Med Microbiol. 2016;65(1):44-47.
11. Bernard P, Toty L, Mounier M, Denis F, Bonnetblanc JM. Early detection of streptococcal group antigens in skin samples by latex particle agglutination. Arch Dermatol. 1987;123(4):468-470.
12. Pallin DJ, Binder WD, Allen MB, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clin Infect Dis. 2013;56(12):1754-1762.
13. Bjornsdottir S, Gottfredsson M, Thorisdottir AS, et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin Infect Dis. 2005;41(10):1416-1422.
14. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999;318(7198):1591-1594.
15. Mokni M, Dupuy A, Denguezli M, et al. Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study. Dermatology. 2006;212(2):108-112.
16. Roujeau JC, Sigurgeirsson B, Korting HC, Kerl H, Paul C. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology.2004;209(4):301-307.
17. Critchley G, Handa A, Maw A, Harvey A, Harvey MR, Corbett CR. Complications of varicose vein surgery. Ann R Coll Surg Engl. 1997;79(2):105-110.
18. Escalante A, Beardmore TD. Risk factors for early wound complications after orthopedic surgery for rheumatoid arthritis. J Rheumatol. 1995;22(10):1844-1851.
19. Lasley DS, Eblen A, Yancey MK, Duff P. The effect of placental removal method on the incidence of postcesarean infections. Am J Obstet Gynecol. 1997;176(6):1250-1254.
20. Thomas TA, Taylor SM, Crane MM, et al. An analysis of limbthreatening lower extremity wound complications after 1090 consecutive coronary artery bypass procedures. Vasc Med.1999;4(2):83-88.
21. Soo JK, Bicanic TA, Heenan S, Mortimer PS. Lymphatic abnormalities demonstrated by lymphoscintigraphy after lower limb cellulitis. Br J Dermatol. 2008;158(6):1350-1353.
22. CREST. Clinical Resource Efficiency Support Team (CREST). Guideline on the management of cellulitis in adults. 2005; http://www.gain-ni.org/.
23. Dermatologie SFd. Erysipelas and necrotizing fasciitis [Erysipele et fasiite necrosante: prise en charge]. Annales de dermatologie et de venereologie. 2001;128:463-482.
24. Eron LJ, Lipsky BA, Low DE, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52 Suppl 1:i3-17.
25. Society BL, Network LS. Consensus Document on the Management of Cellulitis in Lymphoedema. 2016; https://www.lymphoedema.org/. Accessed 12th June 2017.
26. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52.
27. Valeriano-Marcet J, Carter JD, Vasey FB. Soft tissue disease. Rheum Dis Clin North Am. 2003;29(1):77-88, vi.
28. Bersier D, Bounameaux H. Cellulitis and deep vein thrombosis: a controversial association. J Thromb Haemost. 2003;1(4):867-868.
29. Jeune R. Erysipele: donnees epidemiologiques, cliniques et therapeutiques. Ann Dermatol Venereol. 1991;118:545-546.
30. Lindblad B, Wallmark E, Bergqvist D, Cronberg S. Low specificity of the 125I-fibrinogen uptake test for the diagnosis of deep vein thrombosis in patients with erysipelas of the leg. Acta Med Scand.1988;224(4):399-400.
31. Mahe A, Destelle JM, Bruet A, et al. Thromboses veineuses profondes au cours des erysipeles de jambe. Etude Prospective de 40 Observations. Presse Med 1992;21:1022-1024.
32. Perrot JL, Perrot S, Laporte Simitidis S. Existe‐t‐il une place pour les anticoagulants dans le traitement de l’erysipele? Ann Dermatol Venereol 2001;128(352-357).
33. Perrot JL, Perrot S, Paruch PH, et al. Incidence des thromboses veineuses profondes des membres inferieurs au cours et au decours des erysipeles et cellulites de jambes. Etude prospective de 161observations. Ann Dermat Venereol 1997;124:(Suppl.) 68-69.
34. Kilburn SA, Featherstone P, Higgins B, Brindle R. Interventions for cellulitis and erysipelas. Cochrane Database Syst Rev. 2010(6):CD004299.
35. Bernard P, Plantin P, Roger H, et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol. 1992;127(2):155-159.
36. Bernard P, Chosidow O, Vaillant L, French Erysipelas Study G. Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial. BMJ.2002;325(7369):864.
37. Daniel R. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. European Azithromycin Study Group. J Int Med Res. 1991;19(6):433-445.
38. Baig A, Grillage MG, Welch RB. A comparison of erythromycin and flucloxacillin in the treatment of infected skin lesions in general practice. Br J Clin Pract. 1988;42(3):110-115.
39. Thomas MG. Oral clindamycin compared with sequential intravenous and oral flucloxacillin in the treatment of cellulitis in adults: a randomized, double-blind trial. Infectious Diseases in Clinical Practice:. 2014;22(6):330-334.
40. Tarshis GA, Miskin BM, Jones TM, et al. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother. 2001;45(8):2358-2362.
41. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169-2179.
42. Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254-262.
43. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49(6):2260-2266.
44. Pertel PE, Eisenstein BI, Link AS, et al. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract. 2009;63(3):368-375.
45. Corey GR, Wilcox MH, Talbot GH, et al. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65 Suppl 4:iv41-51.
46. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008;46(5):647-655.
47. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008;52(1):37-44.
48. Leman P, Mukherjee D. Flucloxacillin alone or combined with benzylpenicillin to treat lower limb cellulitis: a randomised controlled trial. Emerg Med J. 2005;22(5):342-346.
49. Tan R, Newberry DJ, Arts GJ, Onwuamaegbu ME. The design, characteristics and predictors of mortality in the North of England Cellulitis Treatment Assessment (NECTA). Int J Clin Pract. 2007;61(11):1889-1893.
50. Brindle R, Williams OM, Davies P, et al. Adjunctive clindamycin for cellulitis: a clinical trial comparing flucloxacillin with or without clindamycin for the treatment of limb cellulitis. BMJ Open. 2017;7(3):e013260.
51. Fabian TC, File TM, Embil JM, et al. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg Infect (Larchmt). 2005;6(3):269-282.
52. Rao B, See RC, Chuah SK, Bansal MB, Lou MA, Thadepalli H. Ticarcillin plus clavulanic acid versus moxalactam in the treatment of skin and soft tissue infections. Am J Med. 1985;79(5B):126-129.
53. Covington P, Davenport JM, Andrae D, et al. Randomized, doubleblind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob Agents Chemother. 2011;55(12):5790-5797.
54. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillintazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents. 2005;26(5):357-365.
55. O’Riordan W, Mehra P, Manos P, Kingsley J, Lawrence L, Cammarata S. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis. 2015;30:67-73.
56. Agency EM. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. 2018; https://www.ema.europa.eu/documents/ referral/quinolone-fluoroquinolone-article-31-referral-disablingpotentially-permanent-side-effects-lead_en.pdf. Accessed 18 November 2018, 2018.
57. Zeglaoui F, Dziri C, Mokhtar I, et al. Intramuscular bipenicillin vs. intravenous penicillin in the treatment of erysipelas in adults: randomized controlled study. J Eur Acad Dermatol Venereol. 2004;18(4):426-428.
58. Aboltins CA, Hutchinson AF, Sinnappu RN, et al. Oral versus parenteral antimicrobials for the treatment of cellulitis: a randomized non-inferiority trial. J Antimicrob Chemother. 2015;70(2):581-586.
59. Chan R, Hemeryck L, O’Regan M, Clancy L, Feely J. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. BMJ. 1995;310(6991):1360-1362.
60. Rojas MX, Granados C. Oral antibiotics versus parenteral antibiotics for severe pneumonia in children. Cochrane Database Syst Rev. 2006(2):CD004979.
61. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization
62. for Research and Treatment of Cancer. N Engl J Med. 1999;341(5):312-318.
63. Hoberman A, Wald ER, Hickey RW, et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics. 1999;104(1 Pt 1):79-86.
64. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004;164(15):1669-1674.
65. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14(8):696-705.
66. Cranendonk DR, Opmeer BC, Prins JM, Wiersinga WJ. Comparing short to standard duration of antibiotic therapy for patients hospitalized with cellulitis (DANCE): study protocol for a randomized controlled trial. BMC Infect Dis. 2014;14:235.
67. Bergkvist PI, Sjobeck K. Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Scand J Infect Dis. 1997;29(4):377-382.
68. Johnson S, Leak K, Singh S, et al. Can cycloidal vibration plus standard treatment reduce lower limb cellulitis treatment times? J Wound Care. 2007;16(4):166-169.
69. Carter K, Kilburn S, Featherstone P. Cellulitis and treatment: a qualitative study of experiences. Br J Nurs. 2007;16(6):S22-24,S26-28.
70. Dall L, Peterson S, Simmons T, Dall A. Rapid resolution of cellulitis in patients managed with combination antibiotic and anti-inflammatory therapy. Cutis. 2005;75(3):177-180.
71. Davis JS, Mackrow C, Binks P, et al. A double-blind randomized controlled trial of ibuprofen compared to placebo for uncomplicated cellulitis of the upper or lower limb. Clin Microbiol Infect. 2017;23(4):242-246.
72. Louis ML, Launay F, Guillaume JM, et al. [Necrotizing cellulitis complicating varicella in two children given nonsteroidal antiinflammatory drugs]. Rev Chir Orthop Reparatrice Appar Mot. 2006;92(5):504-507.
73. Smith RJ, Berk SL. Necrotizing fasciitis and nonsteroidal antiinflammatory drugs. South Med J. 1991;84(6):785-787.
74. Zerr DM, Rubens CE. NSAIDS and necrotizing fasciitis. Pediatr Infect Dis J. 1999;18(8):724-725.
75. Aronoff DM, Bloch KC. Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine (Baltimore).2003;82(4):225-235.
76. Forbes N, Rankin AP. Necrotizing fasciitis and non steroidal antiinflammatory drugs: a case series and review of the literature. N Z Med J. 2001;114(1124):3-6.
77. Holder EP, Moore PT, Browne BA. Nonsteroidal antiinflammatory drugs and necrotising fasciitis. An update. Drug Saf. 1997;17(6):369-373.
78. Melis R. No basis for associating nonprescription ibuprofen and similar agents with necrotizing fasciitis. Am J Health Syst Pharm. 1996;53(18):2218-2219.
79. Eter EG, Khazzaka A, Mneimneh W, Karam-Sarkis D, Haddad A, Sarkis R. Does diclofenac increase the risk of cervical necrotizing fasciitis in a rat model? Int J Exp Pathol. 2009;90(1):58-65.